人类抗α-烯醇化酶抗体在白塞病和风湿性疾病患者血清中的存在。

Human anti-alpha-enolase antibody in sera from patients with Behçet's disease and rheumatologic disorders.

机构信息

Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S63-6.

PMID:19796536

Abstract

OBJECTIVE

alpha-Enolase is a target antigen of IgM-type anti-endothelial cell antibody in patients with Behçet's disease (BD). The objective of this study was to assess the reactivity of serum anti-alpha-enolase antibodies in BD and in other rheumatologic diseases, and to evaluate the clinical significance of serum anti-alpha-enolase antibodies in BD.

METHODS

Enzyme-linked immunosorbent assay (ELISA) and immunoblotting were used to examine serum samples from patients with BD (n=100), systemic lupus erythematosus (SLE) (n=50), systemic sclerosis (n=21), rheumatoid arthritis (RA) (n=20), Takayasu's arteritis (n=20), dermatomyositis (n=17), mixed connective tissue disease (MCTD) (n=11), and samples from healthy volunteer donors (n=23). The medical records of patients with BD were reviewed to investigate their clinical characteristics.

RESULTS

Specific positive signals against recombinant human alpha-enolase were detected by IgM ELISA of serum samples from 56 of the 100 BD patients (56.0%), 24 of the 50 SLE patients (48.0%), 15 of the 21 systemic sclerosis patients (71.4%), 13 of the 20 RA patients (65.0%), 10 of the 20 Takayasu's arteritis patients (50.0%), 9 of the 17 dermatomyositis patients (52.9%), and 5 of the 11 MCTD patients (45.5%). The number of BD patients with vascular lesions was significantly higher in the anti-alpha-enolase antibody positive group than in the negative group (p=0.027).

CONCLUSION

We demonstrated the reactivities of serum anti-alpha-enolase antibodies in BD and other rheumatologic diseases with moderate specificity and also found that serum anti-alpha-enolase antibodies in BD can be associated with vascular system involvement.

摘要

目的

α-烯醇化酶是贝赫切特病（BD）患者 IgM 型抗内皮细胞抗体的靶抗原。本研究旨在评估血清抗α-烯醇化酶抗体在 BD 及其他风湿性疾病中的反应性，并评价血清抗α-烯醇化酶抗体在 BD 中的临床意义。

方法

采用酶联免疫吸附试验（ELISA）和免疫印迹法检测 100 例 BD 患者、50 例系统性红斑狼疮（SLE）患者、21 例系统性硬皮病患者、20 例类风湿关节炎（RA）患者、20 例大动脉炎患者、17 例皮肌炎患者、11 例混合性结缔组织病患者及 23 例健康志愿者的血清样本。回顾性分析 BD 患者的临床资料。

结果

在 100 例 BD 患者中，56 例（56.0%）血清样本的 IgM ELISA 对重组人α-烯醇化酶呈特异性阳性信号，在 50 例 SLE 患者中，24 例（48.0%）呈阳性，在 21 例系统性硬皮病患者中，15 例（71.4%）呈阳性，在 20 例 RA 患者中，13 例（65.0%）呈阳性，在 20 例大动脉炎患者中，10 例（50.0%）呈阳性，在 17 例皮肌炎患者中，9 例（52.9%）呈阳性，在 11 例混合性结缔组织病患者中，5 例（45.5%）呈阳性。抗α-烯醇化酶抗体阳性组 BD 患者血管病变的发生率明显高于阴性组（p=0.027）。